Provectus Biopharmaceuticals, INC Form 4 insider transactions
OQB
CEO Edward Pershing reports the conversion of a convertible note into Series D-1 Preferred Stock and updates beneficial ownership.
OQB
CEO Edward Pershing acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals' 2022 Financing.
OQB
CEO Edward Pershing reports the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock of Provectus Biopharmaceuticals.
OQB
CEO Edward Pershing reports the conversion of a promissory note into Series D-1 Convertible Preferred Stock and subsequent conversion of preferred stock into common stock.
OQB
CEO Edward Pershing reports the conversion of a convertible note into Series D-1 Preferred Stock and subsequent conversion of preferred stock into common stock.
OQB
CEO Edward Pershing reports acquisition of convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.
OQB
CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on April 25, 2024.
OQB
Director Edward Pershing reports acquisition of convertible promissory note and preferred stock in Provectus Biopharmaceuticals.
OQB
Director Edward Pershing reports acquisition of convertible promissory note and convertible preferred stock in Provectus Biopharmaceuticals.
OQB
Director Edward Pershing reports the conversion of a convertible note into Series D-1 Convertible Preferred Stock of Provectus Biopharmaceuticals.
OQB
Form 4: Provectus Biopharmaceuticals Director Acquires Convertible Promissory Note and Preferred Stock
Director Edward Pershing acquires an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals.
OQB
Form 4: Provectus Biopharmaceuticals Director Acquires Convertible Promissory Note and Preferred Stock
Director Edward Pershing acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock from Provectus Biopharmaceuticals.
OQB
Director Edward Pershing reports the conversion of a convertible note into Series D-1 Preferred Stock and subsequent conversion of preferred stock into common stock.
OQB
Heather Raines, CFO of Provectus Biopharmaceuticals, reports a $50,000 repayment of an unsecured convertible promissory note and details regarding the note's conversion terms.
OQB
Director Edward Pershing reports acquisition of convertible promissory note and preferred stock in Provectus Biopharmaceuticals.
OQB
Director Edward Pershing reports the conversion of a convertible promissory note into Series D-1 Convertible Preferred Stock of Provectus Biopharmaceuticals.